Related Experiment Videos
A trial of RIT-4237 rotavirus vaccine in 1-month-old infants
European Journal of Pediatrics
|June 1, 1989
Insights
This study shows that the rotavirus vaccine RIT 4237 is safe for infants. It effectively generated rotavirus-IgM-antibodies and reduced rotavirus detection in stool samples.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Rotavirus is a leading cause of severe gastroenteritis in infants globally.
- Development of safe and effective rotavirus vaccines is crucial for public health.
- Early infant vaccination strategies are being explored to reduce disease burden.
Purpose of the Study:
- To evaluate the immunogenicity and safety of the rotavirus vaccine RIT 4237 in young infants.
- To assess the efficacy of the vaccine in preventing rotavirus infection during the first six months of life.
Main Methods:
- A double-blind, placebo-controlled study design was employed.
- Rotavirus vaccine RIT 4237 was administered to infants after four weeks of age.
- Immunological response (rotavirus-IgM-antibodies) and viral shedding in stool samples were monitored.
Main Results:
- The rotavirus vaccine RIT 4237 was well-tolerated in young infants.
- Significantly higher rates of rotavirus-IgM-antibody development were observed in vaccine recipients (57%) compared to placebo (10%).
- Rotavirus was detected in stool samples of 2/12 vaccinees versus 5/12 placebo recipients over six months.
Conclusions:
- Rotavirus vaccine RIT 4237 demonstrates favorable safety and immunogenicity in infants.
- The vaccine shows potential in reducing rotavirus infection in early infancy.
- Further studies are warranted to confirm long-term efficacy and optimal vaccination schedules.
Abstract:
In a double blind placebo-controlled study rotavirus vaccine RIT 4237 was offered to young infants after the fourth week of life. The vaccine was very well tolerated. Fifty-seven out of 100 vaccine recipients and 10 out of 103 placebo recipients developed rotavirus-IgM-antibodies during the 1 month follow-up period. During a 6 month follow-up, stool samples from 2 out of 12 vaccinees and from 5 out of 12 placebo recipients contained rotavirus.